Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

498.48
-1.8700-0.37%
Post-market: 498.480.00000.00%19:30 EDT
Volume:488.40K
Turnover:244.64M
Market Cap:21.38B
PE:17.84
High:505.78
Open:500.62
Low:497.67
Close:500.35
52wk High:609.35
52wk Low:397.00
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.62
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.34
PE(LYR):17.89

Loading ...

United Therapeutics EVP, General Counsel Paul Mahon disposes 8,300 shares for $4.67 million

Reuters
·
May 22

United Therapeutics CEO Martine Rothblatt disposes 9,500 shares for $5.39 million

Reuters
·
May 21

J.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)

TIPRANKS
·
May 20

United Therapeutics Corp : JP Morgan Resumes Coverage With Overweight Rating; Price Target $685

THOMSON REUTERS
·
May 20

United Therapeutics CFO James Edgemond disposes of USD 5.64 million common shares

Reuters
·
May 20

Jefferies Remains a Buy on United Therapeutics (UTHR)

TIPRANKS
·
May 19

United Therapeutics CEO Martine Rothblatt disposes of common shares worth $5.39 million

Reuters
·
May 19

United Therapeutics says TETON-1 study published in NEJM

TIPRANKS
·
May 19

United Therapeutics says Tyvaso meets primary endpoint in TETON-1 IPF trial

Reuters
·
May 19

United Therapeutics Says Pulmonary Arterial Hypertension Treatment Meets Primary Endpoint in Late-Stage Trial

MT Newswires Live
·
May 18

Baidu, Brady And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings
·
May 18

TD Cowen Reaffirms Their Buy Rating on United Therapeutics (UTHR)

TIPRANKS
·
May 18

BRIEF-United Therapeutics Announces Advance Outcomes Study Of Ralinepag

Reuters
·
May 18

United Therapeutics says phase 3 ADVANCE OUTCOMES trial meets primary endpoint for ralinepag

Reuters
·
May 18

United Therapeutics Corp: Phase 3 Advance Outcomes Study Met Its Primary Endpoint

THOMSON REUTERS
·
May 18

United Therapeutics Corporation Announces Advance Outcomes Study of Ralinepag Presented at ATS 2026

THOMSON REUTERS
·
May 18

United Therapeutics wins FDA clearance for UHeart xenotransplant trial

Reuters
·
May 16

United Therapeutics Corp - Express Study to Enroll Initial Cohort of up to Two Participants

THOMSON REUTERS
·
May 16

United Therapeutics Corporation Announces FDA Clearance to Proceed With Uheart Xenotransplantation Clinical Trial

THOMSON REUTERS
·
May 16

United Therapeutics CEO Martine Rothblatt disposes of USD 6.96 million in shares

Reuters
·
May 16